معرفی
Meredith Smith serves as an Adjunct Associate Professor at the University of Southern California while holding a concurrent industry position as Director of Risk Management at Alexion Inc. In her corporate role, she oversees advanced risk management monitoring systems and pioneers digital risk minimization measures, structured benefit-risk assessment frameworks, and patient-centered approaches to pharmaceutical risk management.
Her research spans health services research, pharmaceutical risk management, and behavioral science with deep specialization in drug safety and benefit-risk assessment. She develops methodologies for therapeutic risk minimization program design, implementation, and evaluation, emphasizing patient-centered risk communication strategies and evidence-based safety monitoring systems that bridge clinical practice and regulatory requirements.
Dr. Smith's scholarly work centers on the RIMES Statement framework, establishing standardized quality assessment tools for risk minimization evaluations. Her publications demonstrate evolving expertise from foundational checklist development (2018) to comprehensive systematic reviews of evaluation methodologies (2020), advancing pharmacovigilance science through rigorous analytical frameworks and gray literature integration.
Scientific awards were not documented in the source materials.
While student advising isn't referenced, her professional leadership includes directing international consortia initiatives. She serves as Track Chair for Clinical Safety and Pharmacovigilance at the Drug Information Association Annual Meeting since 2018, co-leading case studies for IMI-PREFER on patient preference elicitation methods, and heading CIOMS XI working groups focused on patient involvement in drug development and safe medication use.
Her collaborative work extends through active participation in FDA-sponsored risk management workshops, CIOMS committees, and IMI-PREFER's international consortium, where she develops consensus recommendations for patient-centered benefit-risk assessment methodologies and risk communication strategies.
